3D image-guided interstitial brachytherapy for primary vaginal cancer: A multi-institutional experience

被引:7
作者
Goodman, Christopher D. [1 ]
Mendez, Lucas C. [1 ]
Velker, Vikram [1 ]
Weiss, Yonatan [2 ]
Leung, Eric [2 ]
Louie, Alexander, V [2 ]
Warner, Andrew [1 ]
Hajdok, George [1 ]
D'Souza, David P. [1 ]
机构
[1] London Hlth Sci Ctr, Dept Radiat Oncol, 800 Commissioners Rd E, London, ON, Canada
[2] Odette Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada
关键词
ESTRO WORKING GROUP; ADAPTIVE BRACHYTHERAPY; RECOMMENDATIONS; PARAMETERS; CARCINOMA;
D O I
10.1016/j.ygyno.2020.10.021
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose/objectives. High dose rate (HDR) interstitial brachytherapy (ISBT) boost is integral for definitive radiation treatment of primary vaginal cancer. Technological advances with CT or MRI guidance provide improved precision and ability to treat more extensively invasive tumors over historical techniques, but reported experience is limited. We sought to provide updated outcome and toxicity data for women with primary vaginal cancer undergoing treatment with a modern ISBT technique. Material/methods. Databases of primary vaginal carcinoma patients treated at two Canadian academic cancer institutions were combined including patient, tumor and treatment characteristics, and survival outcomes and toxicity data. Descriptive statistics, survival estimates based on the Kaplan-Meier method, and univariable/multivariable Cox proportional hazards regression analyses are reported. Results. Between 2002 and 2017, 67 women with primary vaginal cancer were treated with 3D HDR ISBT. FIGO stage distribution was I (22.4%), II(50.8%), III(17.9%),IVa (9.0%). All patients received external beam radiotherapy and HDR ISBT of 500-750 cGy per fraction over 2-4 fractions. Median follow-up was 2.68 years (95% confidence interval: 2.04-6.04). Cumulative rate of grade 3-4 genitourinary/gastrointestinal toxicity was 10.4%. Four patients developed vaginal fistula Progression free survival at 2 and 3 years was 735% and 66.4% for all patients, 78.3% and 75.0% for stage I-II and 61.6% and 462% for stage III-IVa, respectively (log-rank p = 0252). Conclusions. Use of 3D image-guided HDR ISBT boost was safe and resulted in improved survival outcomes compared to historical rates in this series of primary vaginal cancer patients. Prospective study is warranted to better define clinical and dosimetric predictors of local control. (C) 2020 Elsevier Inc. All rights reserved.
引用
收藏
页码:134 / 139
页数:6
相关论文
共 16 条
[11]   Outcomes with image-based interstitial brachytherapy for vaginal cancer [J].
Manuel, Matthias M. ;
Cho, Linda P. ;
Catalano, Paul J. ;
Damato, Antonio. L. ;
Miyamoto, David T. ;
Tempany, Clare M. ;
Schmidt, Ehud J. ;
Viswanathan, Akila N. .
RADIOTHERAPY AND ONCOLOGY, 2016, 120 (03) :486-492
[12]   Brachytherapy improves survival in primary vaginal cancer [J].
Orton, Andrew ;
Boothe, Dustin ;
Williams, Ned ;
Buchmiller, Thomas ;
Huang, Y. Jessica ;
Suneja, Gita ;
Poppe, Matthew ;
Gaffney, David .
GYNECOLOGIC ONCOLOGY, 2016, 141 (03) :501-506
[13]   Recommendations from gynaecological (GYN) GEC-ESTRO working group - ACROP: Target concept for image guided adaptive brachytherapy in primary vaginal cancer [J].
Schmid, Maximilian P. ;
Fokdal, Lars ;
Westerveld, Henrike ;
Chargari, Cyrus ;
Rohl, Lisbeth ;
Morice, Philippe ;
Nesvacil, Nicole ;
Mazeron, Renaud ;
Haie-Meder, Christine ;
Poetter, Richard ;
Nout, Remi A. .
RADIOTHERAPY AND ONCOLOGY, 2020, 145 :36-44
[14]   Factors Affecting Risk of Mortality in Women With Vaginal Cancer [J].
Shah, Chirag A. ;
Goff, Barbara A. ;
Lowe, Kimberly ;
Peters, William A., III ;
Li, Christopher I. .
OBSTETRICS AND GYNECOLOGY, 2009, 113 (05) :1038-1045
[15]   A 30-YEAR EXPERIENCE IN THE MANAGEMENT OF PRIMARY-CARCINOMA OF THE VAGINA - ANALYSIS OF PROGNOSTIC FACTORS AND TREATMENT MODALITIES [J].
STOCK, RG ;
CHEN, ASJ ;
SESKI, J .
GYNECOLOGIC ONCOLOGY, 1995, 56 (01) :45-52
[16]  
Westerveld H, 2020, LANCET ONCOL, V21, pE157, DOI 10.1016/S1470-2045(19)30855-1